Orexo AB (STO:ORX) to Release Q3 2009 Earnings November 10
Rochester, New York 11/04/2009 10:50 PM GMT (TransWorldNews)
Orexo AB (STO:ORX) will release the third quarter earnings for 2009 on Tuesday, November 10. The financial results will be posted in a press release at 8:30 am on the company’s website, www.orexo.com on the Press Releases page of the Investors section.
Penny Stock Professor, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Penny Stock Picks.
Orexo AB confirmed the acceptance of its partner, ProStrakan Group plc’s (LSE:PSK) New Drug Application filing for Abstral has been accepted for review by the US Food and Drug Administration. The product is a sublingual form of fentanyl used to help cancer patients with breakthrough pain episodes. Once the approval process has been completed, Abstral is expected to start selling in the United States during the second half of 2010.
Orexo AB is a Sweden-based company, active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. Its offerings include Diabact UBT, a drug used for the diagnosis of the stomach ulcer bacterium, Helicobacter pylori; the Heliprobe System, which consists of three components, such as HeliCap, BreathCard and Analyzer, and is a near-patient urea breath test system; Edluar, for the treatment of a short-term insomnia, and Abstral, which contains fentanyl, an agent used for the treatment of acute pain in cancer patients. It also has projects in the preclinical phase: OX-MPI, a prostaglandin inhibitor for pain and OX-NLA, a drug against fever in a form of a rapid-acting nasal spray. Orexo has five wholly owned subsidiaries: Pharmacall AB, Kibion AB, Noster System AB, Biolipox AB, Orexo UK, and a 50%-owned affiliate, Prostrakan AB.
Follow us on Twitter: http://www.twitter.com/pennystockspro
Sign up for the free Penny Stock Professor newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
About Us
Penny Stock Professor is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
staff@pennystockprofessor.com
www.pennystockprofessor.com
Email Article to a friend
|
View Profile
Visit Blogs
|
NEWS ALERTS
Receive alerts for
Penny Stock Professor
to your inbox.
Sign up for TransWorldNews Alerts
TransWorldNews, Inc. and its affiliate sites disclaim all liability for information and content provided by clients and appearing within their news and press releases.
